Featured 13F manager
Farallon Capital Management, L.l.c.
San Francisco, CA 87 processed 13Fs on this site · 2021 Q3–2026 Q2
- $21.7B
- 77 Positions
- 2026 Q2
- +23.6% QoQ
- Top 5 29.9%
Portfolio
top 5 29.9% · top 10 44.0%
- RVMD - Revolution Medicines 11.7%
- EA - Electronic Arts 7.5%
- BBIO - Bridgebio Pharma 3.7%
- PTGX - Protagonist Therapeutics 3.6%
- EXEL - Exelixis 3.4%
- LQDA - Liquidia 3.1%
- AMZN - Amazon 2.9%
- LNTH - Lantheus 2.9%
- NTRA - Natera 2.8%
- UNH - Unitedhealth Group 2.4%
- TMO - Thermo Fisher Scientific 2.4%
- ROIV - Roivant Sciences 2.3%
- Other 51.3%
AUM over time
Book
| IQV - IQVIA | 3.40% | Add +7.0% | 2,961,032 | $231.38 | $685M | +194,700 | +$141M |
| EXEL - Exelixis | 3.17% | Add +3.0% | 26,634,500 | $23.99 | $639M | +774,500 | +$74M |
| TMO - Thermo Fisher Scientific | 3.17% | Add +14.9% | 1,203,131 | $530.79 | $639M | +155,600 | +$108M |
| UNH - Unitedhealth Group | 3.14% | Reduce −10.7% | 1,202,600 | $526.47 | $633M | −144,100 | −$46M |
| TRU - Transunion | 3.11% | Reduce −1.2% | 9,122,956 | $68.71 | $627M | −110,300 | −$36M |
| CRM - Salesforce | 2.52% | Reduce −23.8% | 1,925,738 | $263.14 | $507M | −599,900 | −$5M |
| MSFT - Microsoft | 2.50% | Reduce −0.8% | 1,338,578 | $376.04 | $503M | −10,600 | +$77M |
| WAB - Wabtec | 2.48% | Add +21.0% | 3,938,308 | $126.90 | $500M | +682,261 | +$154M |
| ARMK - Aramark | 2.36% | Add +39.2% | 16,899,254 | $28.10 | $475M | +4,763,054 | +$54M |
| NYT - New York Times · CL A | 2.30% | Add +19.0% | 9,476,791 | $48.99 | $464M | +1,512,000 | +$136M |
| GOOG - Alphabet · CL C | 2.20% | Reduce −11.8% | 3,138,540 | $140.93 | $442M | −418,600 | −$27M |
| CBRE - CBRE Group · CL A | 1.96% | Reduce −6.1% | 4,246,000 | $93.09 | $395M | −274,388 | +$61M |
| SPGI - S&P Global | 1.93% | Reduce −11.7% | 882,595 | $440.52 | $389M | −116,800 | +$24M |
| NDAQ - Nasdaq | 1.90% | Add +6310.2% | 6,570,500 | $58.14 | $382M | +6,468,000 | +$377M |
| BSX - Boston Scientific | 1.67% | Add +15.5% | 5,820,257 | $57.81 | $336M | +781,000 | +$70M |
| INTU - Intuit | 1.65% | Reduce −4.2% | 533,000 | $625.03 | $333M | −23,100 | +$49M |
| CHTR - Charter Communications · CL A | 1.54% | Reduce −28.1% | 799,141 | $388.68 | $311M | −312,200 | −$178M |
| CNC - Centene Del | 1.52% | Reduce −7.0% | 4,132,075 | $74.21 | $307M | −313,000 | +$465K |
| NOW - Servicenow | 1.48% | Reduce −11.8% | 421,250 | $706.49 | $298M | −56,300 | +$31M |
| ADI - Analog Devices | 1.47% | Reduce −23.3% | 1,489,100 | $198.56 | $296M | −452,900 | −$44M |
| CSGP - Costar Group | 1.35% | Add +12.0% | 3,121,356 | $87.39 | $273M | +334,500 | +$58M |
| YMM - Full Truck Alliance | 1.33% | Hold | 38,190,495 | $7.01 | $268M | — | — |
| MA - Mastercard · CL A | 1.31% | Add +2.1% | 619,471 | $426.51 | $264M | +13,000 | +$24M |
| SHW - Sherwin Williams | 1.29% | Reduce −20.5% | 832,092 | $311.90 | $260M | −214,700 | −$7M |
| AZNN — | 1.28% | Reduce −36.9% | 3,824,291 | $67.35 | $258M | −2,235,262 | −$153M |
| HWM - Howmet Aerospace | 1.27% | Reduce −0.7% | 4,716,027 | $54.12 | $255M | −31,600 | +$36M |
| BX - Blackstone | 1.10% | Reduce −23.8% | 1,697,351 | $130.92 | $222M | −529,700 | −$16M |
| NTRA - Natera | 1.08% | Add +52.5% | 3,474,883 | $62.64 | $218M | +1,197,000 | +$117M |
| V - VISA · CL A | 1.03% | Add +4.8% | 798,110 | $260.35 | $208M | +36,700 | +$33M |
| RVMD - Revolution Medicines | 0.96% | Add +102.6% | 6,736,854 | $28.68 | $193M | +3,411,374 | +$101M |
| INSP - Inspire Med Sys | 0.86% | Add +100.7% | 855,096 | $203.43 | $174M | +429,000 | +$89M |
| Masimo | 0.76% | Add +476.2% | 1,311,649 | $117.21 | $154M | +1,084,000 | +$134M |
| PTGX - Protagonist Therapeutics | 0.65% | Add +5.3% | 5,734,430 | $22.93 | $131M | +288,000 | +$41M |
| Mirati Therapeutics | 0.59% | Add +102.2% | 2,024,472 | $58.75 | $119M | +1,023,472 | +$75M |
| Sarepta Therapeutics | 0.58% | Reduce −12.0% | 1,210,073 | $96.43 | $117M | −165,127 | −$50M |
| VSTS - Vestis | 0.57% | New | 5,469,753 | $21.14 | $116M | +5,469,753 | +$116M |
| BEAM - Beam Therapeutics | 0.55% | Reduce −8.4% | 4,105,753 | $27.22 | $112M | −376,086 | +$4M |
| UTHR - United Therapeutics | 0.52% | New | 476,000 | $219.89 | $105M | +476,000 | +$105M |
| AGIO - Agios Pharmaceuticals | 0.46% | Add +51.5% | 4,167,602 | $22.27 | $93M | +1,416,773 | +$25M |
| CYTK - Cytokinetics | 0.45% | Add +4896.2% | 1,087,772 | $83.49 | $91M | +1,066,000 | +$90M |
| ROIV - Roivant Sciences | 0.41% | Add +90.4% | 7,336,000 | $11.23 | $82M | +3,482,600 | +$37M |
| IONS - Ionis Pharmaceuticals | 0.39% | Add +113.9% | 1,555,020 | $50.59 | $79M | +828,020 | +$46M |
| BEKE - KE | 0.38% | Hold | 4,758,500 | $16.21 | $77M | — | — |
| EVH - Evolent Health · CL A | 0.35% | Add +13.8% | 2,163,909 | $33.03 | $71M | +263,000 | +$20M |
| Catalent | 0.32% | New | 1,413,000 | $44.93 | $63M | +1,413,000 | +$63M |
| PACB — | 0.30% | Reduce −39.4% | 6,191,370 | $9.81 | $61M | −4,032,750 | −$25M |
| HUM - Humana | 0.28% | Reduce −66.7% | 121,344 | $457.81 | $56M | −243,117 | −$122M |
| BABA - Alibaba Group | 0.21% | Reduce −38.0% | 535,000 | $77.51 | $41M | −327,233 | −$33M |
| PCG - Pg And E | 0.20% | Reduce −46.2% | 2,271,642 | $18.03 | $41M | −1,950,000 | −$27M |
| COR - Cencora | 0.17% | New | 169,000 | $205.38 | $35M | +169,000 | +$35M |
| BHVN - Biohaven | 0.16% | Hold | 750,000 | $42.80 | $32M | — | — |
| Savara | 0.15% | Reduce −42.7% | 6,255,406 | $4.70 | $29M | −4,652,680 | −$12M |
| THC - Tenet Healthcare | 0.14% | Reduce −63.6% | 374,842 | $75.57 | $28M | −655,158 | −$40M |
| Immunogen | 0.12% | New | 842,000 | $29.65 | $25M | +842,000 | +$25M |
| Holding | 0.12% | New | 567,321 | $42.40 | $24M | +567,321 | +$24M |
| VRTX - Vertex Pharmaceuticals | 0.11% | Reduce −72.8% | 55,000 | $406.89 | $22M | −147,000 | −$48M |
| OPCH - Option Care Health | 0.09% | Reduce −34.1% | 567,800 | $33.69 | $19M | −294,200 | −$9M |
| ENTA - Enanta Pharmaceuticals | 0.09% | Add +8.0% | 2,025,000 | $9.41 | $19M | +150,000 | −$2M |
| Zymeworks | 0.09% | Reduce −12.2% | 1,756,000 | $10.39 | $18M | −244,000 | +$6M |
| TAL - Tal Education Group | 0.09% | Hold | 1,365,000 | $12.63 | $17M | — | — |
| SIMO - Silicon Motion Technology | 0.07% | Reduce −76.4% | 246,500 | $61.27 | $15M | −798,500 | −$38M |
| IMVT - Immunovant | 0.07% | Reduce −32.3% | 341,000 | $42.13 | $14M | −163,000 | −$5M |
| LNTH - Lantheus | 0.07% | Reduce −86.7% | 213,327 | $62.00 | $13M | −1,385,173 | −$98M |
| VYGR - Voyager Therapeutics | 0.05% | Hold | 1,292,000 | $8.44 | $11M | — | — |
| Screaming Eagle Acquisitn · CLASS A | 0.05% | Hold | 1,000,000 | $10.60 | $11M | — | — |
| RIO - Rio Tinto | 0.05% | Hold | 137,500 | $74.46 | $10M | — | — |
| TVTX - Travere Therapeutics | 0.05% | Add +302.9% | 1,094,000 | $8.99 | $10M | +822,483 | +$7M |
| NBIX - Neurocrine Biosciences | 0.05% | Reduce −83.8% | 72,398 | $131.76 | $10M | −375,602 | −$41M |
| Holding | 0.05% | Hold | 1,560,500 | $6.03 | $9M | — | — |
| Cazoo Group · CL A | 0.03% | New | 714,240 | $9.50 | $7M | +714,240 | +$7M |
| SLNOEUR - Soleno Therapeutics | 0.03% | Reduce −57.4% | 165,219 | $40.25 | $7M | −222,781 | −$5M |
| HCA - Hca Healthcare | 0.03% | Reduce −88.0% | 20,900 | $270.68 | $6M | −153,500 | −$37M |
| Gossamer Bio | 0.03% | Hold | 6,130,272 | $0.9125 | $6M | — | — |
| Gores Ix · CLASS A | 0.03% | Hold | 500,000 | $10.50 | $5M | — | — |
| VNET - VNET Group | 0.03% | Hold | 1,775,000 | $2.87 | $5M | — | — |
| QTRX - Quanterix | 0.02% | New | 184,000 | $27.34 | $5M | +184,000 | +$5M |
| IOVA - Iovance Biotherapeutics | 0.02% | New | 562,000 | $8.13 | $5M | +562,000 | +$5M |
| CRNX — | 0.02% | Reduce −66.0% | 122,904 | $35.58 | $4M | −239,000 | −$6M |
| Swiftmerge Acquisition · CLASS A | 0.02% | Hold | 300,000 | $10.76 | $3M | — | — |
| Berenson Acquisition I · CL A | 0.01% | Hold | 285,715 | $10.25 | $3M | — | — |
| Bluebird Bio | 0.01% | New | 2,000,000 | $1.38 | $3M | +2,000,000 | +$3M |
| Arya Sciences Acqu Iv · CL A | 0.01% | Hold | 200,000 | $10.88 | $2M | — | — |
| Metals Acquisition | 0.01% | New | 157,500 | $12.36 | $2M | +157,500 | +$2M |
| Marblegate Acquisition · CL A | 0.01% | Hold | 150,000 | $10.43 | $2M | — | — |
| Forte Biosciences | 0.01% | Hold | 1,810,455 | $0.8217 | $1M | — | — |
| Cara Therapeutics | 0.01% | Reduce −6.6% | 1,556,251 | $0.7430 | $1M | −110,340 | −$2M |
| Summit Midstream Partners | 0.01% | Hold | 58,214 | $17.91 | $1M | — | — |
| EDU — | 0.00% | Hold | 13,000 | $73.28 | $953K | — | — |
| Sage Therapeutics | 0.00% | Hold | 42,800 | $21.67 | $927K | — | — |
| MDGL - Madrigal Pharmaceuticals | 0.00% | Hold | 3,319 | $231.38 | $768K | — | — |
| CRL - Charles Riv Labs Intl | 0.00% | Reduce −98.6% | 2,000 | $236.40 | $473K | −144,000 | −$28M |
| BNTX - Biontech Se | 0.00% | Hold | 3,844 | $105.54 | $406K | — | — |
| ALNY - Alnylam Pharmaceuticals | 0.00% | Hold | 2,000 | $191.41 | $383K | — | — |
| HIMS - Hims & Hers Health · CL A | 0.00% | Hold | 42,000 | $8.90 | $374K | — | — |
| Blueprint Medicines | 0.00% | Hold | 4,000 | $92.24 | $369K | — | — |
| APLSUSD - Apellis Pharmaceuticals | 0.00% | Reduce −96.9% | 6,000 | $59.86 | $359K | −188,053 | −$7M |
| AXSM - Axsome Therapeutics | 0.00% | Reduce −96.8% | 4,000 | $79.59 | $318K | −121,653 | −$8M |
| KRYS - Krystal Biotech | 0.00% | Hold | 2,000 | $124.06 | $248K | — | — |
| CHE - Chemed | 0.00% | Hold | 400 | $584.75 | $234K | — | — |
| AM6 - Amicus Therapeutics | 0.00% | Hold | 16,000 | $14.19 | $227K | — | — |
| EHC - Encompass Health | 0.00% | Hold | 3,000 | $66.72 | $200K | — | — |
| R1 Rcm | 0.00% | Add +33.3% | 16,000 | $10.57 | $169K | +4,000 | −$12K |
| COGT - Cogent Biosciences | 0.00% | Hold | 17,000 | $5.88 | $100K | — | — |
Showing top 50 of 103 by value
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2023 Q3
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| Activision Blizzard | 9.54% | Exit | 0 | $93.63 | $1.9B | −20,320,000 | −$1.9B |
| Horizon Therapeutics Pub L | 3.86% | Exit | 0 | $115.69 | $770M | −6,656,823 | −$770M |
| AON - AON PLC · CL A | 1.08% | Exit | 0 | $324.22 | $216M | −665,661 | −$216M |
| ELV - Elevance Health | 0.83% | Exit | 0 | $435.42 | $166M | −381,330 | −$166M |
| CI - The Cigna Group | 0.52% | Exit | 0 | $286.07 | $105M | −366,000 | −$105M |
| XYZ - Block · CL A | 0.52% | Exit | 0 | $44.26 | $103M | −2,336,350 | −$103M |
| DXCM - Dexcom | 0.25% | Exit | 0 | $93.30 | $51M | −544,000 | −$51M |
| Denbury | 0.21% | Exit | 0 | $98.01 | $42M | −425,000 | −$42M |
| United States Stl | 0.10% | Exit | 0 | $32.48 | $21M | −635,000 | −$21M |
| Sdcl Edge Acquisition · CL A | 0.09% | Exit | 0 | $10.60 | $18M | −1,732,500 | −$18M |
| National Instrs | 0.08% | Exit | 0 | $59.62 | $16M | −265,000 | −$16M |
| Ares Acquisition · CL A | 0.08% | Exit | 0 | $10.76 | $15M | −1,425,000 | −$15M |
| Earthstone Energy · CL A | 0.06% | Exit | 0 | $20.24 | $13M | −618,831 | −$13M |
| Chindata Group | 0.05% | Exit | 0 | $8.30 | $11M | −1,300,000 | −$11M |
| SLAM · CL A | 0.03% | Exit | 0 | $10.78 | $6M | −570,396 | −$6M |
| Holding · CL A | 0.02% | Exit | 0 | $10.38 | $4M | −400,000 | −$4M |
| Verve Therapeutics | 0.01% | Exit | 0 | $13.26 | $3M | −211,293 | −$3M |
| OKLO - Altc Acquisition · CL A | 0.01% | Exit | 0 | $10.35 | $1M | −98,300 | −$1M |
| Lufax · CL A | — | Exit | 0 | $1.06 | $636K | −600,000 | −$636K |
| Karuna Therapeutics | — | Exit | 0 | $169.09 | $372K | −2,200 | −$372K |
| HQY - Healthequity | — | Exit | 0 | $73.21 | $205K | −2,800 | −$205K |
| Akero Therapeutics | — | Exit | 0 | $50.50 | $202K | −4,000 | −$202K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 89 | $21.7B | +23.6% | 13F-HR | 8/14/2026 | 000090883426000432 |
| 2026 Q1 | 1 | $1.5B | — | new holds | 8/14/2026 | 000090883426000434 |
| 2026 Q1 | 172 | $17.5B | −17.2% | 13F-HR | 5/15/2026 | 000090883426000240 |
| 2025 Q4 | 1 | $1B | — | new holds | 8/14/2026 | 000090883426000433 |
| 2025 Q4 | 2 | $884M | — | new holds | 5/15/2026 | 000090883426000241 |
| 2025 Q4 | 151 | $21.2B | −13.2% | 13F-HR | 2/17/2026 | 000090883426000087 |
| 2025 Q3 | 144 | $24.4B | — | RESTATEMENT | 2/17/2026 | 000090883426000086 |
| 2025 Q3 | 144 | $24.4B | +5.4% | 13F-HR | 11/14/2025 | 000090883425000353 |
| 2025 Q2 | 1 | $140M | — | new holds | 2/17/2026 | 000090883426000085 |
| 2025 Q2 | 3 | $483M | — | new holds | 11/14/2025 | 000090883425000352 |
| 2025 Q2 | 141 | $23.2B | +29.2% | 13F-HR | 8/14/2025 | 000090883425000248 |
| 2025 Q1 | 1 | $274M | — | new holds | 2/17/2026 | 000090883426000084 |
| 2025 Q1 | 3 | $416M | — | new holds | 11/14/2025 | 000090883425000351 |
| 2025 Q1 | 7 | $2.2B | — | new holds | 8/14/2025 | 000090883425000247 |
| 2025 Q1 | 135 | $17.9B | −9.0% | 13F-HR | 5/15/2025 | 000090883425000177 |
| 2024 Q4 | 1 | $85M | — | new holds | 2/17/2026 | 000090883426000083 |
| 2024 Q4 | 2 | $349M | — | new holds | 11/14/2025 | 000090883425000350 |
| 2024 Q4 | 6 | $2.3B | — | new holds | 8/14/2025 | 000090883425000246 |
| 2024 Q4 | 4 | $333M | — | new holds | 5/15/2025 | 000090883425000180 |
| 2024 Q4 | 138 | $19.7B | −3.5% | 13F-HR | 2/14/2025 | 000090883425000081 |
| 2024 Q3 | 1 | $145M | — | new holds | 11/14/2025 | 000090883425000349 |
| 2024 Q3 | 6 | $1.5B | — | new holds | 8/14/2025 | 000090883425000243 |
| 2024 Q3 | 3 | $216M | — | new holds | 5/15/2025 | 000090883425000179 |
| 2024 Q3 | 2 | $544M | — | new holds | 2/14/2025 | 000090883425000080 |
| 2024 Q3 | 153 | $20.4B | −3.6% | 13F-HR | 11/14/2024 | 000090883424000307 |
| 2024 Q2 | 1 | $120M | — | new holds | 11/14/2025 | 000090883425000348 |
| 2024 Q2 | 5 | $1.2B | — | new holds | 8/14/2025 | 000090883425000245 |
| 2024 Q2 | 1 | $199M | — | new holds | 5/15/2025 | 000090883425000178 |
| 2024 Q2 | 2 | $452M | — | new holds | 2/14/2025 | 000090883425000079 |
| 2024 Q2 | 1 | $149M | — | new holds | 11/14/2024 | 000090883424000324 |
| 2024 Q2 | 157 | $21.2B | −4.2% | 13F-HR | 8/14/2024 | 000090883424000200 |
| 2024 Q1 | 1 | $93M | — | new holds | 11/14/2025 | 000090883425000347 |
| 2024 Q1 | 4 | $1.2B | — | new holds | 8/14/2025 | 000090883425000244 |
| 2024 Q1 | 2 | $159M | — | new holds | 2/14/2025 | 000090883425000078 |
| 2024 Q1 | 1 | $45M | — | new holds | 8/14/2024 | 000090883424000202 |
| 2024 Q1 | 167 | $22.1B | — | RESTATEMENT | 5/24/2024 | 000090883424000159 |
| 2024 Q1 | 167 | $22.1B | +9.8% | 13F-HR | 5/15/2024 | 000090883424000135 |
| 2023 Q4 | 1 | $65M | — | new holds | 11/14/2025 | 000090883425000346 |
| 2023 Q4 | 2 | $548M | — | new holds | 8/14/2025 | 000090883425000250 |
| 2023 Q4 | 5 | $1.1B | — | new holds | 5/15/2024 | 000090883424000141 |
| 2023 Q4 | 150 | $20.1B | +1.0% | 13F-HR | 2/14/2024 | 000090883424000070 |
| 2023 Q3 | 1 | $40M | — | new holds | 11/14/2025 | 000090883425000345 |
| 2023 Q3 | 1 | $40M | — | new holds | 5/15/2024 | 000090883424000138 |
| 2023 Q3 | 2 | $1.4B | — | new holds | 2/14/2024 | 000090883424000077 |
| 2023 Q3 | 1 | $1.9B | — | new holds | 2/12/2024 | 000090883424000049 |
| 2023 Q3 | 159 | $20B | +11.5% | 13F-HR | 11/14/2023 | 000090883423000150 |
| 2023 Q2 | 2 | $669M | — | new holds | 2/14/2024 | 000090883424000076 |
| 2023 Q2 | 5 | $1.4B | — | new holds | 11/14/2023 | 000090883423000157 |
| 2023 Q2 | 1 | $1.2B | — | new holds | 10/26/2023 | 000090883423000134 |
| 2023 Q2 | 165 | $17.9B | +1.3% | 13F-HR | 8/14/2023 | 000090883423000109 |
| 2023 Q1 | 2 | $234M | — | new holds | 2/14/2024 | 000090883424000075 |
| 2023 Q1 | 3 | $389M | — | new holds | 11/14/2023 | 000090883423000156 |
| 2023 Q1 | 1 | $15M | — | new holds | 8/14/2023 | 000090883423000110 |
| 2023 Q1 | 187 | $17.7B | +15.8% | 13F-HR | 5/15/2023 | 000117570723000127 |
| 2022 Q4 | 1 | $171M | — | new holds | 2/14/2024 | 000090883424000074 |
| 2022 Q4 | 3 | $485M | — | new holds | 11/14/2023 | 000090883423000155 |
| 2022 Q4 | 7 | $1B | — | new holds | 5/15/2023 | 000117570723000136 |
| 2022 Q4 | 232 | $15.3B | −9.3% | 13F-HR | 2/14/2023 | 000117570723000051 |
| 2022 Q3 | 1 | $125M | — | new holds | 2/14/2024 | 000090883424000073 |
| 2022 Q3 | 3 | $415M | — | new holds | 11/14/2023 | 000090883423000154 |
| 2022 Q3 | 5 | $411M | — | new holds | 5/15/2023 | 000117570723000135 |
| 2022 Q3 | 4 | $434M | — | new holds | 2/14/2023 | 000090966123000005 |
| 2022 Q3 | 298 | $16.8B | +3.5% | 13F-HR | 11/14/2022 | 000156761922019851 |
| 2022 Q2 | 1 | $115M | — | new holds | 2/14/2024 | 000090883424000081 |
| 2022 Q2 | 3 | $411M | — | new holds | 11/14/2023 | 000090883423000153 |
| 2022 Q2 | 2 | $337M | — | new holds | 5/15/2023 | 000117570723000134 |
| 2022 Q2 | 3 | $136M | — | new holds | 2/14/2023 | 000090966123000003 |
| 2022 Q2 | 9 | $1.2B | — | new holds | 11/14/2022 | 000156761922019862 |
| 2022 Q2 | 297 | $16.3B | −13.7% | 13F-HR | 8/15/2022 | 000156761922015953 |
| 2022 Q1 | 1 | $268M | — | new holds | 11/14/2023 | 000090883423000152 |
| 2022 Q1 | 1 | $314M | — | new holds | 5/15/2023 | 000117570723000133 |
| 2022 Q1 | 1 | $27M | — | new holds | 2/14/2023 | 000090966123000002 |
| 2022 Q1 | 3 | $186M | — | new holds | 11/14/2022 | 000156761922019864 |
| 2022 Q1 | 8 | $1.1B | — | new holds | 8/15/2022 | 000156761922015972 |
| 2022 Q1 | 307 | $18.8B | +0.4% | 13F-HR | 5/16/2022 | 000156761922010736 |
| 2021 Q4 | 1 | $227M | — | new holds | 5/15/2023 | 000117570723000132 |
| 2021 Q4 | 1 | $7M | — | new holds | 11/14/2022 | 000156761922019852 |
| 2021 Q4 | 1 | $115M | — | new holds | 8/15/2022 | 000156761922015968 |
| 2021 Q4 | 2 | $98M | — | new holds | 5/19/2022 | 000156761922011257 |
| 2021 Q4 | 6 | $833M | — | new holds | 5/16/2022 | 000156761922010757 |
| 2021 Q4 | 289 | $18.7B | −5.1% | 13F-HR | 2/14/2022 | 000156761922003965 |
| 2021 Q3 | 1 | $182M | — | new holds | 5/15/2023 | 000117570723000131 |
| 2021 Q3 | 1 | $105M | — | new holds | 8/15/2022 | 000156761922015964 |
| 2021 Q3 | 1 | $57M | — | new holds | 5/19/2022 | 000156761922011256 |
| 2021 Q3 | 3 | $998M | — | new holds | 5/16/2022 | 000156761922010753 |
| 2021 Q3 | 2 | $344M | — | new holds | 2/14/2022 | 000156761922003981 |
| 2021 Q3 | 293 | $19.7B | — | 13F-HR | 11/15/2021 | 000095012321015168 |
About
FARALLON CAPITAL MANAGEMENT, L.L.C.
87 processed 13Fs on this site · 2021 Q3–2026 Q2